Environmental enrichment intervention for Rett syndrome: An individually randomised stepped wedge trial by Downs, Jennepher et al.
Downs et al. Orphanet Journal of Rare Diseases  (2018) 13:3 
DOI 10.1186/s13023-017-0752-8RESEARCH Open AccessEnvironmental enrichment intervention for
Rett syndrome: an individually randomised
stepped wedge trial
Jenny Downs1,2* , Jenny Rodger3, Chen Li4, Xuesong Tan5, Nan Hu1, Kingsley Wong1, Nicholas de Klerk1
and Helen Leonard1Abstract
Background: Rett syndrome is caused by a pathogenic mutation in the MECP2 gene with major consequences for
motor and cognitive development. One of the effects of impaired MECP2 function is reduced production of Brain
Derived Neurotrophic Factor (BDNF), a protein required for normal neuronal development. When housed in an enriched
environment, MECP2 null mice improved motor abilities and increased levels of BDNF in the brain. We investigated the
effects of environmental enrichment on gross motor skills and blood BDNF levels in girls with Rett syndrome.
Methods: A genetically variable group of 12 girls with a MECP2 mutation and younger than 6 years participated in a
modified individually randomised stepped wedge design study. Assessments were conducted on five occasions, two
during the baseline period and three during the intervention period. Gross motor function was assessed using the Rett
Syndrome Gross Motor Scale (maximum score of 45) on five occasions, two during the baseline period and three
during the intervention period. Blood levels of BDNF were measured at the two baseline assessments and at
the end of the intervention period. The intervention comprised motor learning and exercise supplemented
with social, cognitive and other sensory experiences over a six-month period.
Results: At the first assessment, the mean (SD) age of the children was 3 years (1 year 1 month) years ranging from
1 year 6 months to 5 years 2 months. Also at baseline, mean (SD) gross motor scores and blood BDNF levels were
22.7/45 (9.6) and 165.0 (28.8) ng/ml respectively. Adjusting for covariates, the enriched environment was associated
with improved gross motor skills (coefficient 8.2, 95%CI 5.1, 11.2) and a 321.4 ng/ml (95%CI 272.0, 370.8) increase in
blood BDNF levels after 6 months of treatment. Growth, sleep quality and mood were unaffected.
Conclusions: Behavioural interventions such as environmental enrichment can reduce the functional deficit in Rett
syndrome, contributing to the evidence-base for management and further understanding of epigenetic mechanisms.
Environmental enrichment will be an important adjunct in the evaluation of new drug therapies that use BDNF pathways
because of implications for the strengthening of synapses and improved functioning.
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Rett syndrome is caused by a pathogenic variant in the
MECP2 gene [1] resulting in major consequences for the
development of motor functioning and cognitive skills.
Motor effects include loss of hand function skills during
a regression period [2] with a slow decline in gross
motor skills over time [3]. Environmental enrichment
models are components of most early intervention pro-
grams for children with a neurodevelopmental disability
evaluated most frequently in cerebral palsy [4]. Although
similar programs also exist for Rett syndrome, their
evidence base is poor [5]. In a single subject design study
with three affected girls, participation in conductive
education improved gross motor skills [5].
One of the effects of impaired MECP2 function is re-
duced production of Brain Derived Neurotrophic Factor
(BDNF), a protein required for normal neuronal devel-
opment and brain function [6]. There is some clinical
evidence of a role for BDNF in Rett syndrome pathogen-
esis [7–9]. Relationships between the type of BDNF poly-
morphism and phenotype have been demonstrated, with
more clinical severity and earlier seizure onset when
limited to the p.Arg168* mutation [7]. Overall, the age
of seizure onset has been observed as earlier [9] or
slightly later [7] in individuals with the heterozygous
(Val/Met) irrespective of mutation type. In another
study, no child with a heterozygous (Val/Met) BDNF
polymorphism developed epilepsy earlier than 2 years
[8]. Environmental enrichment reduces cellular and be-
havioural deficits in animal models of disorders includ-
ing Huntington’s disease, Fragile X and Down syndrome
[10], and clinical improvements have been found in
Parkinson’s and Alzheimer’s diseases [11] and cerebral
palsy [4]. When housed in an enriched environment,
MECP2 null mice have demonstrated improved motor
abilities and increased levels of BDNF in the brain [12].
Environmental enrichment could benefit children in the
early stages of Rett syndrome and increased BDNF levels
could be associated with improvements. Environmental
enrichment could effect wellbeing more generally. For
example, difficulties getting to sleep and staying asleep
[13] occur frequently in Rett syndrome [14]. Exercise
could improve these symptoms and potentially improve
behavioural outcomes such as mood [15].
Based on the incidence of Rett syndrome in
Australia [16], approximately 1000 girls of the 8.6
million girls born each year in China and approxi-
mately 222 of the nearly 2 million girls born each
year in the US will have Rett syndrome. Whilst Rett
syndrome is rare, many girls are affected globally.
This study examined the effects of environmental en-
richment on gross motor skills and BDNF protein
levels in Rett syndrome. As secondary outcomes,
sleep quality and mood were also evaluated.Methods
Participants and setting
The international database InterRett established in 2002
[17] was used for recruitment to this study. Families
with a child with a confirmed clinical diagnosis of Rett
syndrome [18] aged two to 6 years were invited to par-
ticipate, provided their child also had a pathogenic
MECP2 mutation. Assessments and intervention were
conducted at the Rett Syndrome Comprehensive
Research Institute (RSCRI) in Shenzhen, China in 2016.
Trial design
A modified stepped wedge individually randomized con-
trolled trial [19] was conducted with different girls
crossing over from control to intervention conditions at
different time points. The baseline period was either
one, two or 3 months as determined randomly and
thereafter the intervention period was 6 months. The
stepped wedge design was chosen because 1) variability
between genotypes limited our capacity to randomize into
two similar groups within the available sample [20, 21]
and 2) it was considered reasonable and standard practice
for the girls to have to wait to receive the program [5].
Computer generated randomisation (Version 14.1,
StataCorp, College Station, TX) was conducted by a
researcher who had not had any contact with the families.Intervention
The intervention provided a rich sensori-motor environ-
ment and included multiple supported activities selected
to target individual goals in the development of motor
skills and endurance. Activities focused particularly on
balance and walking and included a high volume of
practice aiming to increase BDNF production [22]. The
intervention was also consistent with Motor Learning
Theory [23], including opportunities for practice, intrin-
sic and extrinsic feedback, judicious use of rest periods,
and performance of tasks in a variety of conditions that
provided choice [23]. Each motor activity was supple-
mented with visual (eg, toys, applications), auditory (eg,
songs, praise), taste (eg, snacks of food), vestibular (eg,
balance shift) and tactile (eg, walking on differently tex-
tured surfaces) stimulation to build the richness of the
sensori-motor environment (Fig. 1). The intervention
was conducted for 2 to 3 h on six mornings per week with
one-on-one supervision provided by a physiotherapist at
RSCRI. Each therapist-child dyad worked individually and
in small groups to provide additional social stimulation.
Outcomes
The primary outcome was gross motor skill measured
using the Rett Syndrome Gross Motor Scale (RSGMS)
[21], comprising 15 items for sitting, standing, walking
Fig. 1 Schematic diagram showing the components of the enriched environment intervention and hypothesised effects of increased BDNF levels
and improved functional abilities
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level of assistance (no assistance, mild, moderate or
maximal assistance/unable) and using a 0 to 3 scale with
3 representing better function. The scale has demon-
strated strong internal consistency, expected relation-
ships between scores, age and genotype, excellent
test-retest reliability and an observed difference of four
points in an individual would represent change beyond
within-subject error [21]. Gross motor skills were video-
taped at RSCRI and a blinded assessor coded the gross
motor skills. Gross motor data were collected at the be-
ginning and end of the baseline period and at 2-monthly
intervals during the intervention period.
The secondary outcomes were blood levels of the BDNF
protein, growth, sleep quality and behaviour. Blood samples
were taken at the beginning and end of the baseline period
and then again after the six-month intervention period. For
each test, blood was taken in the afternoon after lunch to
standardise the time of day and relation with food intake
[24]. Samples were collected in anticoagulant tubes and
stored at −80 degrees C. At the time of testing, the whole
blood was lysed with 3% triton X-100 (Amresco, Ohio)
with sonification for 5 s for 20 times with a 10-s interval
between each disruption (Scientz98-III, Scientz Biotechnol-
ogy Co Ltd., Ningbo) [25]. Disrupted cell membranes
were discarded by centrifuging the samples at 2000 g
for 15 min at 4 °C. The supernatant was aliquoted
for storage and the BDNF protein concentration was
measured with commercially available two-site sand-
wich enzyme-linked immunoabsorbent assay (ELISA)
kits (RAYBIOTECH, Norcross GA US; catalogue
number ELH-BDNF Lot: 0520160106). Each blood
sample was diluted *100 and tested in triplicateaccording to the manufacturer’s instructions. Mean
values of the three concentrations of BDNF (ng/ml)
were used for analysis.
The other secondary outcomes were measured at each
of the assessment occasions including weight (kg) and
supine height (cm) and BMI was derived. Sleep quality
was measured using the disorders of initiating and main-
taining sleep (DIMS) subscale of the parent-reported
Sleep Disturbance Scale for Children (SDSC), compris-
ing seven items rated on a five-point Likert scale with
higher scores indicating more difficulties [26]. Sleep
hygiene was measured with the Sleep Habits Question-
naire [27] as an adjusting variable because of potential
effects on sleep quality [28]. Mood was measured using
the mood subscale of the parent-completed Rett
Syndrome Behaviour Questionnaire (RSBQ), with eight
items rated on a 0 to 2 scale with 2 representing greater
behavior problems [29].
Previously collected data reported to the InterRett data-
base included the results of genetic testing for the type of
MECP2 mutation, age of developmental regression and
the presence of epilepsy. A portion of one of the blood
samples was used for Sanger sequencing for genotyping of
the BDNF gene (SNP rs6265) to test the type of BDNF
polymorphism (Val/Val, Val/Met, Met/Met).
The trial was registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12615001286538). Ethical
approval was provided by the Human Research Ethics
Committees at University of Western Australia, Perth
(RA/4/1/7782) and the Shenzhen Children’s Hospital,
Shenzhen (2015 [014]) and all families provided
informed consent prior to participation according to
the Declaration of Helsinki.
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Based on previous data [5], we estimated a sample size of
12 girls would give us 80% power to detect a within-subject
improvement in RSGMS scores of at least 4 points using a
5% two-tailed test. Descriptive statistics were used to sum-
marise the baseline characteristics of the participants.
Mean (SD) and median (range) values of the continuous
outcome variables (RSGMS score, blood BDNF level, BMI,
DIMS subscale score, RSBQ mood subscale score) at each
time point and for each BDNF polymorphism were pre-
sented. A subset of RSGMS item scores were missing and
they were imputed using last observation carried forward
method. Intra-class correlation coefficients (ICC) (using
two-way mixed effects models) and their 95% confidence
intervals (CI) were employed to estimate the within-subject
consistency in values of outcome variables during the base-
line period (i.e. between time point 1 and 2).
Linear mixed-effects regression models with random
intercepts were used to investigate the effects of treat-
ment on the outcome variables. Time points 1 and 2
were free of intervention and thus the treatment variable
was coded 0. For time points 3, 4 and 5 the treatment
variable was coded 1, 2, and 3 respectively as it was
hypothesised that there would be a dose-response rela-
tionship between intervention and outcome. Age at as-
sessment was used as the time variable in the model.
Univariable, as well as multivariable models, were fitted.
In addition to age at regression, other potential con-
founders including blood BDNF level and the Malow
sleep routines score [27] were used in the multivariable
analyses where appropriate. Because blood BDNF level
at time point 5 was not available for 2 participants, these
individuals were removed from modelling involving
blood BDNF level. Crude and adjusted estimates and
their 95% confidence intervals were reported. All data
analyses and data management were undertaken using
Stata version 14.2.
Results
The study was discussed with 13 families registered with
InterRett of whom 12 (92.3%) provided informed consent.Table 1 Mean (SD) values for the primary and secondary outcomes
periods
Outcome Baseline per
Assessment
N Mean (S
Rett Syndrome Gross Motor Scale (/45) 12 22.7 (9.6
Blood Brain Derived Neurotrophic Factor (ng/ml) 11 165.0 (2
BMI 12 15.2 (1.4
Sleep Disturbance Scale for Children (DIMS subscale, /35)* 12 15.8 (5.5
Rett Syndrome Behaviour Questionnaire (Mood subscale, /16)* 12 8.6 (3.6)
*One child unwell at assessment 4 and another at assessment 5The mean (SD) age of the children at the first baseline as-
sessment was 3.0 (1.1) years ranging from 1.5 to 5.2 years.
Their mean (SD) age at regression had been 1.5 (0.4) years
ranging from 1 to 2.3 years. Each had a pathogenic
MECP2 mutation and most of the common mutation cat-
egories were represented (C-terminal [n = 1], Early trun-
cating [n = 1], Large deletion [n = 1], p.Arg168* [n = 1],
p.Arg255* [n = 2], p.Arg270* [n = 3], p.Arg294* [n = 1] and
p.Thr158Met [n = 2]). The BDNF polymorphism was
homozygous (Val/Val) in three girls, heterozygous (Val/
Met) in seven and negative (Met/Met) in two girls. At the
first baseline assessment, five girls walked independently,
four walked with assistance and three were unable to walk.
One girl aged 18 months (p.Arg255*, Val/Met BDNF poly-
morphism) had been diagnosed with epilepsy prior to the
commencement of the study which was managed with
Levitircetam, and two girls developed epilepsy during the
intervention period and commenced Valproate.
Mean (SD) values for each of the outcomes at each of
the assessments are shown in Table 1. The RSGMS score
was similar at baseline assessments 1 and 2, whether the
duration of baseline was 1 month (ICC 0.977 [CI 0.751,
0.998], p = 0.003), two (ICC 0.987 [CI 0.813, 0.999], p =
0.001) or 3 months (ICC 0.976 [CI 0.772, 0.998], p =
0.003). The baseline blood BDNF levels were less vari-
able when the duration of baseline was 1 month (ICC
0.615 [CI -0.31, 0.968], p = 0.120) than for 2 months
(ICC 0.223 [CI -0.957, 0.969], p = 0.392) and 3 months
(ICC 0.309 [CI -1.042, 0.939], p = 0.327), but the average
differences were small at 27.7 ng/ml, 40.6 ng/ml and
9.9 ng/ml respectively. In total, video for 116/900 gross
motor items were missing over the five testing occasions
equating to 2 of 15 items per assessment per participant.
Most missing items were the most complex skills and
the previously observed level was carried forward as a
conservative estimate. Because of illness (one each with
lower respiratory tract infection and seizures), two gross
motor assessments and post intervention blood tests
could not be measured.
Compared to baseline, the within-person RSGMS score
increased by 3.4 (95%CI 1.5, 5.3) points after 2 months ofat each assessment during the baseline and intervention
iod Intervention period
1 Assessment 2 Assessment 3 Assessment 4 Assessment 5
D) N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
) 12 22.4 (10.4) 12 25.5 (8.9) 12 27.6 (8.4) 12 29.8 (9.7)
8.8) 12 146.1 (50.1) – – – – 10 510.0 (104.2)
) 12 15.1 (1.5) 12 14.6 (1.0) 11 14.7 (1.5) 11 15.0 (1.6)
) 12 16 (6.1) 12 15.6 (4.3) 11 15.4 (7.2) 11 14.4 (5.6)
12 7 (3.6) 12 7.6 (3.6) 11 7.3 (3.0) 11 8.7 (3.5)
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(95%CI 5.1, 11.2) after 6 months of treatment, adjusting
for age of regression and current age. RSGMS scores in-
creased 1.1 (95%CI 0.1, 2.2) point per additional month in
age at the time of regression. For the 10 girls with post
intervention BDNF data, there was a 10.3 (95%CI 3.2,
17.4) point increase in RSGMS score after 6 months of
treatment adjusting for the effects of age at regression,
current age and BDNF levels. Compared to baseline,
BDNF levels increased by 321.4 ng/ml (95%CI 272.0,
370.8) after 6 months of treatment, adjusting for age at re-
gression, current age and RSGMS score. BDNF levels in-
creased an additional 39.0 ng/ml (95%CI 15.2, 62.4) for
each additional year in age, adjusting for age at regression
and the RSGMS score (Table 2).
Adjusting for covariates, BMI decreased slightly after 2
months of treatment (−0.6 kg/m2 [−1.2. -0.1]) but there-
after increased and after 6 months of treatment was
similar to baseline values (−0.3 kg/m2 [−1.2, 0.6]); the
DIMS subscale scores remained similar to baseline
values throughout the treatment period as did the mood
subscale of the RSBQ (Table 3).
The median (range) RSGMS and blood BDNF levels at
each assessment are presented in Table 4 for each of the
BDNF polymorphisms. Girls with the heterozygous poly-
morphism (Val/Met) had the lowest median RSGMS
scores and blood BDNF levels at baseline but the magni-
tude of increase after 6 months of treatment was similar
to girls with the Val/Val or Met/Met polymorphisms. The
increase in score as a proportion of the baseline score was
highest in girls with the Val/Met polymorphism (62%)
compared with those with the Val/Val (29%) or Met/Met
(32%) polymorphisms (Table 4).Table 2 Univariable and multivariable models showing relationships b
scores (n = 12) and blood brain derived neurotrophic factor (BDNF) lev
Outcomes Coefficient (95%CI) P value Coe
Univariable model (n = 12) Mult
RSGMS
Treatment after 2 months 2.7 (0.8, 4.6) 0.01 3.4 (
Treatment after 4 months 4.6 (2.2, 7.0) < 0.001 5.7 (
Treatment after 6 months 6.6 (3.7, 9.5) < 0.001 8.2 (
Age (year) 1.0 (−3.1, 5.2) 0.63 −1.6
Age at regression (month) 1.1 (
Blood BDNF (time-varying)
Univariable model (n = 10) Mult
Blood BDNF
Treatment after 6 months 342.9 (297.0, 388.8) < 0.001 321.
Age (year) 30.1 (10.7, 49.5) 0.002 39.0
Age at regression (month) −4.8
RSGMS (time-varying) 2.4 (Discussion
Motor learning and exercise supplemented with rich
social, cognitive and other sensory experiences had posi-
tive effects on motor functioning in Rett syndrome.
Adjusting for covariates, participants gained on average
eight points on the 45-point motor scale after 6 months
treatment, much greater in magnitude than the response
observed in the conductive education study after 6
months [5]. Importantly, gross motor improvement was
observed for children with different abilities at baseline
and included achievement of independent sitting, walk-
ing or transition skills such as sitting to standing. We
did find that children with a later age at regression, usu-
ally observed with MECP2 mutations associated with
milder clinical severity [30], gained slightly more gross
motor skills over the treatment period. It is not known
whether a longer treatment period was necessary to
achieve greater gross motor gains for those who had ex-
perienced earlier regression.
General health issues were not compromised. Growth
and sleep patterns were maintained over the study
period and the intervention did not appear to affect
mood, although the mood subscale of the RSBQ devel-
oped for Rett syndrome may not have been sensitive to
changes in mood in preschool children. Two girls in the
current study developed epilepsy during the intervention
period which was not inconsistent with the natural his-
tory of Rett syndrome where 50% develop epilepsy by 5
years of age [31]. We observed that an environmental
enrichment intervention could be safely delivered to
girls with Rett syndrome.
To our knowledge, this is the first intervention study
investigating serum BDNF levels as an outcome in aetween intervention, Rett Syndrome Gross Motor Scale (RSGMS)
els (n = 10) adjusting for relevant confounders
fficient (95%CI) P value Coefficient (95%CI) P value
ivariable model – 1 (n = 12) Multivariable model – 2 (n = 10)
1.5, 5.3) 0.001
3.3, 8.2) < 0.001
5.1, 11.2) < 0.001 10.29 (3.20, 17.38) 0.004
(−6.0, 2.9) 0.492 −0.12 (−4.70, 4.47) 0.960
0.1, 2.2) 0.028 1.06 (0.07, 2.05) 0.035
−0.01 (−0.03, 0.01) 0.412
ivariable model (n = 10)
4 (272.0, 370.8) < 0.001
(15.6, 62.4) 0.001
(−10.4, 0.9) 0.098
−0.6, 5.4) 0.119
Table 3 Univariable and multivariable findings for relationships between treatment, BMI and other secondary behavioural outcomes
(n = 12)
Outcomes Univariable model Multivariable model
Coefficient (95%CI) P value Coefficient (95%CI) P value
BMI
Treatment after 2 months −0.5 (−1, 0.0) 0.042 −0.6 (−1.2, −0.1) 0.026
Treatment after 4 months −0.4 (−1.0, 0.2) 0.157 −0.6 (−1.3, 0.1) 0.096
Treatment after 6 months 0.0 (−0.6, 0.6) 0.938 −0.3 (−1.2, 0.6) 0.49
Age (years) −0.3 (−0.9, 0.3) 0.333 −0.3 (−1.1, 0.5) 0.519
Age at regression (months) 0.0 (−0.2, 0.2) 0.707
Gross motor assessment score (time-varying) 0.0 (0.0, 0.1) 0.307
Sleep Disturbance Scale for Children - DIMS subscale
Treatment after 2 months 0.4 (−1.8, 2.6) 0.73 0.2 (−2.1, 2.4) 0.892
Treatment after 4 months 0.3 (−2.1, 2.7) 0.81 0.1 (−2.4, 2.6) 0.961
Treatment after 6 months 0.1 (−2.4, 2.6) 0.93 0 (−2.8, 2.8) 0.998
Age (years) −2.6 (−4.7, −0.6) 0.01 −2.2 (−4.8, 0.3) 0.082
Age at regression (months) −0.1 (−0.7, 0.4) 0.6
Sleep hygiene score −0.1 (−0.3, 0.2) 0.567
Rett Syndrome Behaviour Questionnaire – Mood subscale
Treatment after 2 months −0.1 (−1.8, 1.6) 0.921 −0.2 (−2.0, 1.5) 0.804
Treatment after 4 months −0.2 (−2.0, 1.7) 0.874 −0.4 (−2.3, 1.5) 0.691
Treatment after 6 months 1 (−0.9, 2.9) 0.31 0.7 (−1.3, 2.7) 0.496
Age (years) −0.8 (−2.1, 0.6) 0.275 −0.2 (−1.7, 1.4) 0.789
Age at regression (months) −0.2 (−0.5, 0.2) 0.316
Table 4 Median and range Rett Syndrome Gross Motor Scale (RSGMS) scores and blood brain derived neurotrophic factor (BDNF)
levels at each assessment by BDNF gene polymorphism (Val/Val, Val/Met, Met/Met)
Baseline period Intervention period
Assessment 1 Assessment 2 Assessment 3 Assessment 4 Assessment 5
RSGMS
N Median (range) N Median (range) N Median (range) N Median (range) N Median (range)
Val/Val 3 31
(30–34)
3 32
(30–33)
3 32
(30–35)
3 34
(32–37)
3 39
(30–39)
Val/Met 7 16
(4–29)
7 16
(0–29)
7 23
(9–33)
7 24
(13–34)
7 26
(13–38)
Met/Met 2 28.5
(27–30)
2 28.5
(27–30)
2 31.5
(30–33)
2 33.5
(33–34)
2 37.5
(36–39)
Blood BDNF
Val/Val 3 173.8
(152.1–177.9)
3 166.6
(126.7–214.2)
– – – – 3 493.1
(436.3–689.0)
Val/Met 6a 156.3
(117.5–232.6)
7 129.5
(69.8–211.4)
– – – – 6a 446.1
(387.1–619.6)
Met/Met 2 172.39
(166.9–177.9)
2 147.5
(82.1–212.9)
– – – – 1a 566.7
(566.7–566.7)
aMissing blood sample at assessment 1 due to technical difficulties and missing blood samples at assessment 5 due to ill health
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syndrome. Baseline BDNF levels in our sample were
generally lower than in children in the general popula-
tion measured using the same assay [32], similar to ani-
mal studies where BDNF protein levels in the brain of
MecP2 mutant mice were reduced compared with wild-
type levels [33]. In contrast, BDNF levels in children
with autism spectrum disorder [34] and Down syndrome
are high [35] compared with the general population.
BDNF levels vary with factors such as the time of the
day [24, 36] and age [36], and further standardized
assessment in children with Rett syndrome is necessary
to understand BDNF production in Rett syndrome and
explain any variance between different neurodevelop-
mental disorders.
An important mechanism underpinning the beneficial
effects of environmental enrichment is believed to be in-
creased levels of BDNF, which promotes the survival and
growth of neurones, synaptic efficiency and neuroplasti-
city [6]. In studies of MeCP2 knockout mice, strategies
to improve BDNF signalling have included administra-
tion of IGF-1 [37] and the provision of an enriched en-
vironment [12, 38]. In 12 girls with a MECP2 mutation,
peripherally administered IGF-1 was associated with
modest improvement in autonomic and behavioural fea-
tures [39]. General population studies suggest that aer-
obic exercise is associated with increases in BDNF levels
[40]. In our present study, the provision of an enriched
and supported environment intervention that included
exercise was associated with a threefold increase in
serum BDNF levels alongside parallel gains in gross
motor skills. Although we cannot discern the ingredients
of the intervention that were associated with changes in
BDNF levels, we recognize that administration of any
exercise regimen for young children with movement def-
icits requires training and learning in an appealing envir-
onment that promotes, rewards and challenges activity.
We also included the polymorphism status of the BDNF
gene in our analyses. The substitution of valine for me-
thionine at codon 66 (Val66Met) is a common BDNF
polymorphism which can impair intracellular trafficking
and secretion of the resulting mature BDNF protein [33]
and in Mecp2 knockout mice, reduced dendritic growth
and complexity and reduced frequency of postsynaptic
currents were found [41]. In Rett syndrome, the presence
of the Val/Met BDNF polymorphism has been associated
with slightly greater clinical severity [7] consistent with
the current study where girls with the Val/Met poly-
morphism had the poorest gross motor skills at baseline.
Two of the three individuals with seizures had the Val/
Met polymorphism and the other the Met/Met poly-
morphism. One of these Val/Met individuals had seizure
onset prior to 2 years of age in contrast with another study
there were no individual with this genotype experiencedseizures prior to 2 years of age [8]. It would be reasonable
to expect that not all individuals with Rett syndrome
would benefit equally from increased BDNF because of
the type of MECP2 mutation or BDNF polymorphism. A
six-week high-intensity exercise program resulted in cog-
nitive benefits for children in the general population com-
pared to an active control group, and the greatest
improvements were observed in children who were Met
carriers compared to those with homozygous BDNF status
[42]. Similar to this recent literature, we also observed dif-
ferent responses to training with the change in gross
motor scores as a proportion of baseline scores being
greatest for girls with the Val/Met polymorphism. In con-
trast to previous studies of mainly Caucasian girls with
Rett syndrome [7–9], more girls in the current sample
had the Val/Met rather than the Val/Val polymorphism
similar to other studies of Asian populations [43]. Investi-
gations of larger sample sizes are needed to investigate the
relationships between the BDNF polymorphism and re-
sponses to an enriched environment.
We did not conduct a conventional randomized con-
trolled trial because of sample size availability and the
striking variability in motor abilities between different
genotypes, which limited our capacity to randomize into
two similar groups. A small proportion of video data
was missing and our sample size precluded longitudinal
modelling to estimate the missing data. We therefore
carried forward the last known value for each item for
each child, consistent with our observations that no
child lost skill over the course of the intervention and
resulting in a conservative estimate of functioning. We
also do not know whether increased blood levels of
BDNF over the study period were reflected in brain tis-
sues, but we are encouraged by the parallel increases in
gross motor skills and evidence that serum BDNF can
cross the blood-brain barrier in young animals [44]. We
nevertheless implemented strategies to minimise bias.
We recruited children with minimal exposure to inter-
ventions enabling us to more clearly identify an effect;
we randomised individuals to the duration of the base-
line period and then assessed under control and inter-
vention conditions; we standardised the timing of blood
draws to reduce diurnal variation in serum BDNF level
[24]; and we used a blinded assessor to code the video
data. We still captured variability in MECP2 mutation
and BDNF polymorphism types and different levels of
baseline skills but recommend replication of our
methods to accumulate more evidence.
Conclusions
Environmental enrichment has long been applied as an
intervention to ameliorate the effects of brain disorders
on functioning. We suggest that the enriched environ-
ment has benefits for children with Rett syndrome and
Downs et al. Orphanet Journal of Rare Diseases  (2018) 13:3 Page 8 of 9clinicians and therapists should plan therapy and activity
opportunities accordingly. New drug, cell and gene ther-
apies for neurological disorders including Rett syndrome
are being developed that use BDNF pathways [45]. We
propose that behavioural interventions such as environ-
mental enrichment will be an important adjunct in the
evaluation of these new therapies because environmental
enrichment also has implications for functioning.
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